Clinical Trials Logo

Filter by:
NCT ID: NCT00271128 Active, not recruiting - Shortness of Breath Clinical Trials

NT-proBNP for Evaluation of the Dyspneic Patient in the Emergency Room and the Medical Ward

Start date: October 2005
Phase: N/A
Study type: Observational

The proposed study intends to evaluate the impact of the NT-proBNP assay on the diagnosis of heart failure in patients with dyspnea of unknown etiology presenting to the emergency room and admitted to the medical wards.

NCT ID: NCT00247299 Active, not recruiting - Port Wine Stain Clinical Trials

Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform

Start date: May 2005
Phase: N/A
Study type: Interventional

The Intense Pulsed Light (IPL) technology, by selective phototermolysis, is used for eliminating, among other application, benign vascular lesions and unwanted leg veins. Light energy heats the deeper structures of the skin. IPL devices provide a broad wavelength spectrum of 515 to 1200 nm and fluence from 10 to 40 J/cm at o.5-1 Hz.The light is focused by a reflector and then transmitted through various filters that cut off the lower wavelength range of the emitted light; therefore, only those wavelengths longer than these of the filters are transmitted. objectives: 1. evaluate and optimize the clinical performance of the Luminis ONE platform for each of the aforementioned clinical applications. 2. Reconfirm the parameter settings for each of the aforementioned clinical applications. 3. Confirm the user friendly design of the device, in aspects of software (user interface) and various technical operational features.

NCT ID: NCT00226525 Active, not recruiting - Clinical trials for Coronary Stent Restenosis

Effect of Metal Skin Sensitivity on Restenosis After Stent Implantation

Start date: February 2005
Phase: N/A
Study type: Interventional

This trial is intended to find wether there is a connection between allergy to metals and reooclusion of stents in the coronary arteries

NCT ID: NCT00107198 Active, not recruiting - Clinical trials for Ann Arbor Stage II Childhood Hodgkin Lymphoma

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Start date: January 2, 2006
Phase: Phase 2
Study type: Interventional

This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.

NCT ID: NCT00052156 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage IV Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

NCT ID: NCT00052130 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage III Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

NCT ID: NCT00045032 Active, not recruiting - Breast Cancer Clinical Trials

Trastuzumab in Treating Women With Primary Breast Cancer

Start date: December 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether trastuzumab is effective in treating primary breast cancer in women who have completed adjuvant chemotherapy. PURPOSE: This randomized phase III trial is studying two different regimens of trastuzumab and observation only to compare how well they work in treating women with breast cancer.

NCT ID: NCT00006249 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Start date: June 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma. PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.

NCT ID: NCT00005052 Active, not recruiting - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Start date: December 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma. PURPOSE: This randomized phase III trial is studying vaccine therapy to see how well it works compared to observation alone in treating patients with primary stage II melanoma.

NCT ID: NCT00003643 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Combination Chemotherapy in Treating Men With Germ Cell Cancer

Start date: October 1998
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy may be more effective for germ cell cancer. PURPOSE: This randomized phase II/III trial is studying two different regimens of combination chemotherapy and comparing how well they work in treating men with germ cell cancer.